Adiponectin-Based Therapeutics for Cancer Treatment

Abstract

Adiponectin is an adipokine predominantly produced from adipocytes and exerts potent growth inhibitory activity in a wide range of cancer cells. Decreased expression and/or function of adiponectin are associated with increased risks and aggressive development of cancers with poor prognoses. To restore the expression level of endogenous adiponectin and to activate its functional pathways represent promising strategies for the prevention and treatment of cancer, especially in obese patients. However, the development of recombinant adiponectin as a therapeutic agent has been hampered by the complexity of its structures and the highly diversified functionality of this magic molecule. Here, the application of different adiponectinbased prophylactics and therapeutics in cancer treatment will be thoroughly reviewed and scrutinized.

Adiponectin-expressing Treg facilitate T lymphocyte development in thymic nurse cell complexes

“…Adiponectin protein forms trimers, hexamers and high-molecular-weight (HMW) species with distinct biological activities 8,9 . The circulating levels of adiponectin are inversely correlated with many cardiometabolic abnormalities and cancer diseases 10,11 . Mice lacking the alleles of ADIPOQ are more susceptible to the development of obesityrelated metabolic and malignant diseases, whereas replenishment of adiponectin decreases glucose production, restores insulin sensitivity, reduces visceral adiposity, protects against hepatic steatosis and inflammatory liver injuries, attenuates the development of atherosclerotic vascular disease, and inhibits cancer development [12][13][14][15][16][17][18] .…”